Overview

Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia

Status:
Completed

Trial end date:
2004-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the effect of treatment with darbepoetin alfa on peak oxygen consumption (peak VO2) in subjects with symptomatic CHF and anemia.

Phase:

N/A

Details

Lead Sponsor:

Amgen

Treatments:

Darbepoetin alfa